Despite this fact, amplification of 9p24.1 (locus-containing JAK2/PDL1/PDL2), a frequently observed cytogenetic abnormality in classical HL patients, induces aberrant overexpression of PD-L1 on tumor cells [65], suggesting that tumor PD-L1 might dampen anti-tumor immunity. The gene discussed is JAK2; the disease is neoplasm.